In the BioHarmony Drug Report Database

"Preview" Icon

Lorlatinib

Lorbrena, Lorviqua (lorlatinib) is a small molecule pharmaceutical. Lorlatinib was first approved as Lorbrena on 2018-11-02. It is used to treat in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against proto-oncogene tyrosine-protein kinase ROS and ALK tyrosine kinase receptor. In addition, it is known to target tyrosine-protein kinase Fes/Fps. Lorbrena’s patents are valid until 2036-07-27 (FDA).

 

Trade Name

 

Lorviqua
 

Common Name

 

lorlatinib
 

ChEMBL ID

 

CHEMBL3286830
 

Indication

 

non-small-cell lung carcinoma
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Lorlatinib structure rendering